Category News

Datroway® Wins U.S. Approval as First TROP2 ADC for First-Line Metastatic TNBC Treatment

Datroway Gains Landmark U.S. Approval for First-Line Treatment of Metastatic Triple-Negative Breast Cancer In a major advancement for breast cancer treatment, Daiichi Sankyo and AstraZeneca have announced that the U.S. Food and Drug Administration (FDA) has approved Datroway® (datopotamab deruxtecan-dlnk)…

Read MoreDatroway® Wins U.S. Approval as First TROP2 ADC for First-Line Metastatic TNBC Treatment

DiaMedica Therapeutics Reaches 75% Enrollment Milestone in Phase 2/3 ReMEDy2 Acute Ischemic Stroke Trial

DiaMedica Therapeutics announced that it has reached approximately 75% enrollment in its ReMEDy2 Phase 2/3 acute ischemic stroke trial, marking a key development milestone in the study. DiaMedica Therapeutics Inc. announced a significant development in its late-stage clinical program for…

Read MoreDiaMedica Therapeutics Reaches 75% Enrollment Milestone in Phase 2/3 ReMEDy2 Acute Ischemic Stroke Trial

Texas Cancer Institute Adopts Kallisio Technologies Stentra™ as Standard Oral Immobilization Solution

Texas Cancer Institute Implements Kallisio Technologies Stentra™ as Standard-of-Care for Precision Radiation Therapy After Successful Clinical Pilot Kallisio announced that the Texas Cancer Institute has officially transitioned its use of the company’s Stentra™ system from a pilot evaluation phase into…

Read MoreTexas Cancer Institute Adopts Kallisio Technologies Stentra™ as Standard Oral Immobilization Solution

Atrandi Biosciences Strengthens Leadership Team to Drive Global Growth of Capsule-Based Single-Cell Technologies

Atrandi Biosciences Enhances Executive Team to Drive International Growth of Its Innovative Single-Cell Technology Atrandi Biosciences has expanded its executive and governance leadership team with the appointment of Sam Ropp as Chief Commercial Officer and Susan Tousi as Chairman of…

Read MoreAtrandi Biosciences Strengthens Leadership Team to Drive Global Growth of Capsule-Based Single-Cell Technologies

TRIANA Biomedicines Appoints Mohan Bala as COO and Expands Scientific Advisory Board

TRIANA Biomedicines Appoints Mohan Bala as COO and Expands Scientific Advisory Board With Industry Experts TRIANA Biomedicines has announced a series of major leadership and scientific advisory appointments as the company continues expanding its molecular glue degrader platform and advancing…

Read MoreTRIANA Biomedicines Appoints Mohan Bala as COO and Expands Scientific Advisory Board

Artivion, Inc. Completes Acquisition of Endospan After FDA Approval of NEXUS® Aortic Arch System

Endospan Completes Acquisition by Artivion, Inc. After FDA Approval of the NEXUS® Aortic Arch System Endospan has announced the completion of its acquisition by Artivion in a deal that significantly strengthens Artivion’s position in the global aortic repair market and…

Read MoreArtivion, Inc. Completes Acquisition of Endospan After FDA Approval of NEXUS® Aortic Arch System

BAXFENDY Becomes First FDA-Approved Aldosterone Synthase Inhibitor for Hypertension Adults

BAXFENDY Becomes First FDA-Approved Aldosterone Synthase Inhibitor for Adults With Hypertension in the U.S. AstraZeneca has announced that the U.S. Food and Drug Administration has approved BAXFENDY for the treatment of hypertension in adults whose blood pressure remains inadequately controlled…

Read MoreBAXFENDY Becomes First FDA-Approved Aldosterone Synthase Inhibitor for Hypertension Adults

Signatera CDx Receives FDA Approval as Companion Diagnostic for Muscle-Invasive Bladder Cancer

Natera Receives FDA Approval for Signatera CDx as First Blood-Based MRD Companion Diagnostic in Muscle-Invasive Bladder Cancer Natera announced that the U.S. Food and Drug Administration has approved Signatera CDx as a companion diagnostic for use alongside adjuvant atezolizumab, marketed…

Read MoreSignatera CDx Receives FDA Approval as Companion Diagnostic for Muscle-Invasive Bladder Cancer

Kariya and NeuraLight Partner to Evaluate Brain Effects of Next-Generation GLP-1 Therapies

Kariya and NeuraLight Collaborate to Evaluate Brain Effects of Next-Generation GLP-1 Therapies Kariya Pharmaceuticals and NeuraLight have announced a strategic partnership aimed at advancing the development of next-generation brain-focused GLP-1 therapies for neurodegenerative diseases, including Parkinson’s disease and Alzheimer’s disease.…

Read MoreKariya and NeuraLight Partner to Evaluate Brain Effects of Next-Generation GLP-1 Therapies